The global market for Pemetrexed Injection is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Pemetrexed Injection market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Pemetrexed Injection market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Pemetrexed Injection market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Pemetrexed Injection market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Pemetrexed Injection players cover Eagle Pharmaceuticals, AuroMedics Pharma, Teva Pharmaceutical Industries, Taro Pharma and Seacross Pharmaceuticals, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This latest report provides a deep insight into the global Pemetrexed Injection market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Pemetrexed Injection market, with both quantitative and qualitative data, to help readers understand how the Pemetrexed Injection market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
The study segments the Pemetrexed Injection market and forecasts the market size by Type (0.5g Bottle and 0.2g Bottle,), by Application (Non Squamous Non-Small Cell Lung Cancer and Squamous Cell Non-Small Cell Lung Cancer.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Segmentation by application
Non Squamous Non-Small Cell Lung Cancer
Squamous Cell Non-Small Cell Lung Cancer
Segmentation by region
Middle East & Africa
Major companies covered
Teva Pharmaceutical Industries
Simcere Pharmaceutical Group
Jiangsu Anda Pharmaceutical
Yangtze River Pharmaceutical Group
Hansoh Pharmaceutical Group Company南京制药厂
Nanjing Pharmaceutical Factory
Vianex S.A.-Plant C
Hainan Jinrui Pharmaceutical
Chapter 1: Scope of Pemetrexed Injection, Research Methodology, etc.
Chapter 2: Executive Summary, global Pemetrexed Injection market size (sales and revenue) and CAGR, Pemetrexed Injection market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Pemetrexed Injection sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Pemetrexed Injection sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Pemetrexed Injection market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Eagle Pharmaceuticals, AuroMedics Pharma, Teva Pharmaceutical Industries, Taro Pharma, Seacross Pharmaceuticals, Simcere Pharmaceutical Group, Qilu Pharmaceutical, Pfizer and Jiangsu Anda Pharmaceutical, etc.
Chapter 14: Research Findings and Conclusion